Clinical trial
A Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Ricolinostat in Chinese Subjects
NCT05193851 is registered in ClinicalTrials.gov with Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Ricolinostat in Chinese Subjects
- Lead sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 12, 2022
- Completion date
- January 6, 2023
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.